Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON: NKTR-102 vs Physician's Choice in Advanced Breast Cancer
NCT01492101Phase 3Completed
- Sponsor
- Nektar Therapeutics
- Start
- Dec 2011
- Primary completion
- Apr 2016
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of etirinotecan pegol in breast cancer, sponsored by Nektar Therapeutics. Started Dec 2011; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01492101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01492101.